New draft guidance from FDA cautions companies on the use of relative frequencies when discussing efficacy and risk information in direct-to-consumer promotional labeling and advertisements. The guidance from CDER’s Office of Prescription Drug Promotion, CBER and CVM covers the presentation of quantitative efficacy and risk information in DTC promotional labeling and advertis... Read More